Last updated on March 2018

Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A.


Brief description of study

This trial is conducted in China. The aim of this trial is to evaluate the clinical efficacy of turoctocog alfa in treatment of bleeding episodes in Chinese patients with severe haemophilia A (FVIII1%).

Clinical Study Identifier: NCT02938585

Contact Investigators or Research Sites near you

Start Over

Novo Nordisk Investigational Site
Beijing, China

Novo Nordisk Investigational Site
Chonqqing, China

Novo Nordisk Investigational Site
Fuzhou, China

Novo Nordisk Investigational Site
Guangzhou, China

Novo Nordisk Investigational Site
Guiyang, China

Novo Nordisk Investigational Site
Wuhan, China

Novo Nordisk Investigational Site
Xining, China

Novo Nordisk Investigational Site
Shanghai, China

Novo Nordisk Investigational Site
Tianjing, China

Novo Nordisk Investigational Site
Kunming, China

Novo Nordisk Investigational Site
Hangzhou, China